Why the study?
Does hydralazine compared to methyldopa improve the rapidity of lowering mean arterial blood pressure in postpartum patients with pregnancy-induced hypertension?
Does hydralazine compared to methyldopa improve the rapidity of lowering mean arterial blood pressure in postpartum patients with pregnancy-induced hypertension?
Hydralazine appears to be a more effective and less costly medication than methyldopa for rapidly lowering mean arterial blood pressure in the immediate postpartum period for patients with pregnancy-induced hypertension.
Answers are grounded in this paper and cite their sources.
Hydralazine may be preferred over methyldopa for faster MAP reduction in early postpartum PIH; extends small RCT evidence to guide acute management.
Despite the importance of pregnancy-induced hypertension (PIH), there are few published investigations of therapeutic approaches for the postpartum management of such patients. Twenty-six gravida patients with PIH were prospectively studied during the first 24 hours after delivery while receiving intravenous magnesium sulfate. Each study subject was randomly assigned to a group also systemically administered either hydralazine or methyldopa. During the study interval, hourly measurements of blood pressure, pulse, fluid intake, and urine output were recorded. Hydralazine was found to be superior in its ability to effect more rapidly a lower mean arterial blood pressure. No significant differences in urine output or time until onset of diuresis were noted among treatment groups. No serious side effects were encountered with the use of either antihypertensive agent. Based on these preliminary findings, it appears that hydralazine is the less costly and more effective medication to lower mean arterial blood pressure in the immediate postpartum period.
No takes yet. Share an insight, caveat, or question.
Griffis et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: